glutamine and Neuroendocrine Tumors

glutamine has been researched along with Neuroendocrine Tumors in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agarwal, P; Angara, B; Bhowmick, NA; Duong, F; Gottlieb, RA; Haldar, S; Liu, Z; Madhav, A; Mishra, R; Placencio, V; Posadas, EM; Rohena-Rivera, K; Tripathi, M; Wagner, S	1
Allen, E; Hanahan, D; Li, L; Miéville, P; Peng, MW; Saghafinia, S; Warren, CM	1

Other Studies

2 other study(ies) available for glutamine and Neuroendocrine Tumors

Article	Year
Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. The Journal of clinical investigation, 2018, 10-01, Volume: 128, Issue:10 Topics: Animals; Fibroblasts; Gene Silencing; Glutamine; Humans; Male; Mice; Neoplasm Proteins; Neuroendocrine Tumors; Prostatic Neoplasms; ras GTPase-Activating Proteins	2018
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling. Cell reports, 2016, 05-10, Volume: 15, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation	2016

Article

Year

Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming.

The Journal of clinical investigation, 2018, 10-01, Volume: 128, Issue:10

Topics: Animals; Fibroblasts; Gene Silencing; Glutamine; Humans; Male; Mice; Neoplasm Proteins; Neuroendocrine Tumors; Prostatic Neoplasms; ras GTPase-Activating Proteins

2018

Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling.

Cell reports, 2016, 05-10, Volume: 15, Issue:6

Topics: Angiogenesis Inhibitors; Animals; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glycolysis; Humans; Imidazoles; Indazoles; Indoles; Intestinal Neoplasms; Lactic Acid; Membrane Transport Proteins; Mice; Models, Biological; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Signal Transduction; Sirolimus; Stomach Neoplasms; Sunitinib; TOR Serine-Threonine Kinases; Up-Regulation

2016